Kenvue Inc. (KVUE) to Issue Quarterly Dividend of $0.21 on November 27th

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, October 17th,RTT News reports. Shareholders of record on Wednesday, November 13th will be given a dividend of 0.205 per share on Wednesday, November 27th. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date is Wednesday, November 13th.

Kenvue has a payout ratio of 67.2% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Kenvue to earn $1.22 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 67.2%.

Kenvue Trading Up 3.1 %

Kenvue stock opened at $23.68 on Monday. The stock has a 50-day moving average of $22.65 and a two-hundred day moving average of $20.54. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. Kenvue has a one year low of $17.67 and a one year high of $23.72. The stock has a market cap of $45.35 billion, a PE ratio of 43.05, a price-to-earnings-growth ratio of 3.10 and a beta of 1.36.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.41% and a net margin of 6.88%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the business posted $0.31 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. On average, research analysts anticipate that Kenvue will post 1.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KVUE has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a research note on Tuesday, September 24th. Bank of America boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, UBS Group upped their price objective on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.